DYNAMOS

Non-small Cell Lung Cancer

Merck Sharp & Dohme LLCSmall moleculePhase 2Active

CCC

50/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 59/ 100

Competitive context

1205 Active assets in the Non-small Cell Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB
Onartuzumab Hoffmann-La Roche	Phase 3	BBB

View all 50 →

Same molecule, other indications

DYNAMOS is also rated in:

malignant pancreatic neoplasmDormant

B

Indicative ·

62 / 100

metabolic dysfunction-associated steatohepatitisDormant

B

Indicative ·

60 / 100

MASH - Metabolic Dysfunction-Associated SteatohepatitisDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.